Drug Profile
Peginterferon alfa-2a - Rhein Minapharm Biogenetics
Alternative Names: Hansenula-derived peginterferon alpha-2a; PEG-IFN alpha-2a - Rhein Minapharm Biogenetics; PEG-interferon alpha-2a - Rhein Minapharm Biogenetics; Peginterferon alpha-2a - Rhein Minapharm Biogenetics; Reiferon RetardLatest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Rhein Minapharm Biogenetics
- Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
- Mechanism of Action Immunostimulants; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 31 Jan 2005 Launched for Hepatitis C in Egypt (SC)
- 28 Dec 2004 Registered for Hepatitis C in Egypt (SC)